PUBLIC COMPANY
saveVerismo Therapeutics Inc
updated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1SynKIR-310 for Relapsed/Refractory B-NHL
- phase1SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
- —A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
- —Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that